Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04534205
Title	A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)
Acronym	AHEAD-MERIT
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	BioNTech SE
Indications	oropharynx cancer laryngeal squamous cell carcinoma oral squamous cell carcinoma head and neck squamous cell carcinoma hypopharynx cancer
Therapies	BNT113 + Pembrolizumab Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG